Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer (FLIPPER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02690480
Recruitment Status : Active, not recruiting
First Posted : February 24, 2016
Last Update Posted : February 5, 2020
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Spanish Breast Cancer Research Group

Tracking Information
First Submitted Date  ICMJE January 5, 2016
First Posted Date  ICMJE February 24, 2016
Last Update Posted Date February 5, 2020
Actual Study Start Date  ICMJE February 17, 2016
Actual Primary Completion Date January 11, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 18, 2016)
Efficacy in terms of the rate of Progression-Free Survival (PFS) [ Time Frame: at 1 year ]
assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by the investigator
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 17, 2019)
  • Progression-Free Survival (PFS) [ Time Frame: an average of 40-44 months since FPFV (approximately Ago2019) ]
    the time from the date of randomization to the first documented progressive disease, using RECIST version 1.1, or death from any cause, whichever occurs first
  • Objective Response Rate (ORR) [ Time Frame: at 1 year and to be updated with further analyses ]
    the percentage of patients with a complete or partial response out of the patients who had measurable disease at baseline.
  • Clinical Benefit Rate (CBR) [ Time Frame: at 1 year and to be updated with further analyses ]
    Complete Response (CR) plus Partial Response (PR) plus stable disease (SD) lasting ≥ 24 weeks (+/- 2 weeks) according to RECIST version 1.1.
  • Overall Survival (OS). [ Time Frame: an average of 40-44 months since FPFV(approximately Ago2019). A formal analysis will be performed when at least 60% of patients have died (2021) ]
    the time from the date of randomization to the date of death from any cause.
  • 1 year and 2 year survival probabilities [ Time Frame: 1 year and 2 year ]
    the percentage of patients without death from any cause out of the randomised patients (calculated using the Kaplan-Meier technique).
  • Incidence of adverse events occurring during the study, and their relatedness to the study drug/medications (safety and tolerability). [ Time Frame: at 1 year and to be updated with further analyses ]
    Safety will be assessed by standard clinical and laboratory tests. Adverse events will be graded according to NCI-CTCAE version 4.0
  • Patient reported outcomes of health-related quality of life based on EORTC QLQ-C30 Global Health Status/Quality of Life and Physical Function [ Time Frame: at 1 year and to be updated with further analyses ]
    Generic aspects of quality of life will be assessed. Changes (mean score) from baseline and time to deterioration will be analyzed.Health Status/QoL and Physical Function and EORTC QLQ-BR23 Breast Module from baseline
  • Patient reported outcomes of health-related quality of life based on EORTC QLQ-BR23 Breast Module. [ Time Frame: at 1 year and to be updated with further analyses ]
    Disease-specific treatment measurements will be assessed. Changes (mean score) from baseline and time to deterioration will be analyzed.
Original Secondary Outcome Measures  ICMJE
 (submitted: February 18, 2016)
  • Progression-Free Survival (PFS) [ Time Frame: an average of 40-44 months since FPFV (approximately Ago2019) ]
    assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by the investigator
  • Objective Response Rate (ORR) [ Time Frame: at 1 year and to be updated with further analyses ]
    Complete Response (CR) plus Partial Response (PR) according to RECIST version 1.1
  • Clinical Benefit Rate (CBR) [ Time Frame: at 1 year and to be updated with further analyses ]
    CR plus PR plus stable disease (SD) lasting ≥ 24 weeks (+/- 2 weeks) according to RECIST version 1.1.
  • Overall Survival (OS). [ Time Frame: an average of 40-44 months since FPFV(approximately Ago2019). A formal analysis will be performed when at least 60% of patients have died (2021) ]
  • 1 year and 2 year survival probabilities [ Time Frame: 1 year and 2 year ]
  • Incidence of adverse events occurring during the study, and their relatedness to the study drug/medications (safety and tolerability). [ Time Frame: at 1 year and to be updated with further analyses ]
    Safety will be assessed by standard clinical and laboratory tests. Adverse events will be graded according to NCI-CTCAE version 4.0
  • Patient reported outcomes of health-related quality of life based on EORTC QLQ-C30 Global Health Status/Quality of Life and Physical Function [ Time Frame: at 1 year and to be updated with further analyses ]
    Generic aspects of quality of life will be assessed. Changes (mean score) from baseline and time to deterioration will be analyzed.Health Status/QoL and Physical Function and EORTC QLQ-BR23 Breast Module from baseline
  • Patient reported outcomes of health-related quality of life based on EORTC QLQ-BR23 Breast Module. [ Time Frame: at 1 year and to be updated with further analyses ]
    Disease-specific treatment measurements will be assessed. Changes (mean score) from baseline and time to deterioration will be analyzed.
Current Other Pre-specified Outcome Measures
 (submitted: February 18, 2016)
Biomarker analyses [ Time Frame: Up to 5 years ]
Identify promising biomarkers of response to fulvestrant plus palbociclib and fulvestrant plus placebo.
  • Identify promising biomarkers of primary resistance to fulvestrant plus palbociclib and fulvestrant plus placebo.
  • Identify promising biomarkers of acquired resistance to fulvestrant plus palbociclib and fulvestrant plus placebo.
  • Identify promising biomarkers to monitor response to fulvestrant plus palbociclib and fulvestrant plus placebo
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer
Official Title  ICMJE Phase II Study to Compare Fulvestrant (F) 500mg Plus Placebo vs F 500mg Plus Palbociclib as First Line Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer Sensitive to Endocrine Therapy. GEICAM/2014-12
Brief Summary This is an international, multicentre, double-blind, controlled, randomized phase II study comparing the efficacy and safety of fulvestrant in combination with palbociclib versus fulvestrant plus placebo in postmenopausal women with HR-positive/HER2-negative metastatic breast cancer who have received ≥5 years of endocrine therapy in the adjuvant setting as treatment for early disease and remained disease free for > 12 months following its completion or have "de novo" metastatic disease.
Detailed Description

Patients must have at least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline and is suitable for repeated assessment by CT, MRI or plan x-ray. Patients with bone-only disease must have a lytic or mixed (lytic + blastic) lesion, which has not been previously irradiated and can be accurately assessed by CT/MRI or x-ray. Approximately 190 patients will be randomized 1:1 between the experimental arm (approximately 95 patients treated with fulvestrant plus palbociclib) and the control arm (approximately 95 patients treated with fulvestrant plus placebo).

Primary Objective:

• To compare the efficacy of fulvestrant in combination with palbociclib versus fulvestrant plus placebo in terms of the rate of Progression-Free Survival (PFS) at 1 year in postmenopausal women with HR-positive/HER2-negative metastatic breast cancer previously treated with endocrine therapy for at least 5 years and remaining disease free for more than 12 months following its completion or have "de novo" metastatic disease

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Breast Neoplasms
Intervention  ICMJE
  • Drug: PD-0332991 (Palbociclib)

    Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.

    Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first

    Other Name: Ibrance
  • Drug: Fulvestrant

    Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)

    Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first

    Other Name: Faslodex
  • Drug: Placebo

    Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.

    Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs

Study Arms  ICMJE
  • Experimental: PD-0332991(Palbociclib)+fulvestrant(FaslodexTM)
    Fulvestrant 500mg, on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
    Interventions:
    • Drug: PD-0332991 (Palbociclib)
    • Drug: Fulvestrant
  • Active Comparator: Placebo+fulvestrant(FaslodexTM)
    Fulvestrant 500mg on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
    Interventions:
    • Drug: Fulvestrant
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: May 17, 2019)
189
Original Estimated Enrollment  ICMJE
 (submitted: February 18, 2016)
190
Estimated Study Completion Date  ICMJE December 2023
Actual Primary Completion Date January 11, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. The patient has signed and dated the informed consent document and it has been obtained before conducting any procedure specifically for the study.
  2. Availability of a tumor tissue sample, archival (primary tumour) or from the metastatic lesions (preferable) for the central ER, PgR and HER2 testing.
  3. Histological/cytological confirmation of breast cancer with evidence of metastatic disease (loco-regional or distant), not amenable to resection or radiation therapy with curative intent.
  4. Documented positive hormone receptor status (> or = 1% of tumour cells with oestrogen receptor [ER] and/or progesterone receptor [PgR] expression) based on central testing on the most recent tumour biopsy.
  5. Documented HER2-negative tumour based on central testing on the most recent tumour biopsy. HER2-negative tumour is determined as immunohistochemistry score 0/1+ or negative by in situ hybridization (FISH/CISH/SISH) defined as a HER2/CEP17 ratio <2 or for single probe assessment a HER2 copy number <4.
  6. Patients must have received at least 5 years of endocrine therapy in the adjuvant setting as treatment for early disease and remained disease free for more than 12 months following its completion or have "de novo" metastatic disease. Patients that have been scheduled 5 years with adjuvant endocrine therapy and stopped treatment, by patient's own decision, after completing at least 3 years of treatment, can be also be included as long as they have remained free of disease 3 years after discontinuing the endocrine therapy.
  7. Patients must have at least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline and is suitable for repeated assessment by CT, MRI, plan x-ray or physical examination. Clinical lesions will only be considered measurable when they are superficial and ≥10mm diameter as assessed using callipers (e.g. skin nodules). Patients with bone-only disease must have a lytic or mixed (lytic + blastic) lesion, which has not been previously irradiated and can be accurately assessed by CT/MRI according to RECIST version 1.1.
  8. Postmenopausal patient, defined as a woman fulfilling any one of the following criteria (based on the NCCN definition of menopause [National Comprehensive Cancer Network 2008]):

    • Prior bilateral oophorectomy.
    • Age > 60 years.
    • Age ≤ 60 years and with amenorrhea for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and follicle stimulating hormone and estradiol in the postmenopausal range.
  9. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2.
  10. At least 18 years of age.
  11. Life expectancy ≥ 12 weeks.
  12. Adequate organ and bone marrow function:

    • ANC ≥ 1,500/mm3 (1.5x109/L);
    • Platelets ≥ 100,000/mm3 (100x109/L);
    • Haemoglobin (Hgb) ≥ 9g/dL (90g/L);
    • Serum creatinine ≤ 1.5xUpper Limit of Normal (ULN) or estimated creatinine clearance ≥ 60ml/min as calculated using the method standard for the institution;
    • Total serum bilirubin ≤ 1.5xULN (<3xULN if Gilbert´s disease);
    • AST and/or ALT ≤ 3xULN (≤5xULN if liver metastases present);
    • Alkaline Phosphatase (AP) ≤ 2.5xULN (≤5xULN if bone or liver metastases present).
  13. Patients consent to biological sample provision for biomarker exploratory analysis.
  14. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

  1. Prior systemic therapy for metastatic disease. Note: patients with a local recurrent disease treated with surgery (R0) and receiving a "second hormonal adjuvant therapy for five years" will be allowed, provided they have remained disease free for more than 12 months following its completion.
  2. Have "de novo" locally advanced disease.
  3. Current use of food or drugs known to be potent CYP3A4 inhibitors, drugs known to be potent CYP3A4 inducers, and drugs that are known to prolong the QT interval.
  4. Presence of life-threatening metastatic visceral disease, defined as extensive hepatic involvement, or any degree of brain or leptomeningeal involvement (past or present), or symptomatic pulmonary lymphangitis spread, or any known bone marrow infiltration due to breast cancer. Patients with discrete pulmonary parenchymal metastases are eligible, provided their respiratory function is not significantly compromised as a result of disease.
  5. Treatment with a non-approved or experimental drug within 4 weeks before randomization.
  6. Prior treatment with any CDK4/6 inhibitor or fulvestrant.
  7. Current or prior malignancy within previous 5 years (other than breast cancer or adequately treated basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix).
  8. History of:

    • Bleeding diathesis (i.e., disseminated intravascular coagulation [DIC], clotting factor deficiency) or long-term (>6 months) anticoagulant therapy (other than antiplatelet therapy and low dose coumarin derivatives provided that the International Normalised Ratio (INR) is less than 1.6). Hypersensitivity to active or inactive excipients of fulvestrant, palbociclib/placebo or castor oil.
    • Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the trial protocol, e.g. uncontrolled cardiac disease or uncontrolled diabetes mellitus.
  9. QTc interval > 480msec, family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation or Torsade de Pointes.
  10. Uncontrolled electrolyte disorders that can compound the effects of a QTc-prolonging drug (eg, hypocalcaemia, hypokalaemia, hypomagnesaemia).
  11. Impairment of gastro-intestinal (GI) function or GI disease that may significantly alter the absorption of palbociclib, such as history of GI surgery which may result in intestinal blind loops and patients with clinically significant gastro-paresis, short bowel syndrome, unresolved nausea, vomiting, active inflammatory bowel disease or diarrhoea of CTCAE grade > 1.
  12. Prior hematopoietic stem cell or bone marrow transplantation.
  13. Known human immunodeficiency virus infection.
  14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Ireland,   Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02690480
Other Study ID Numbers  ICMJE GEICAM/2014-12
2015-002437-21 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Spanish Breast Cancer Research Group
Study Sponsor  ICMJE Spanish Breast Cancer Research Group
Collaborators  ICMJE AstraZeneca
Investigators  ICMJE
Study Director: Study Director Hospital del Mar
PRS Account Spanish Breast Cancer Research Group
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP